Jubilant Biosys Opens Noida Facility to Boost Chemistry Scale-Up

Jubilant Biosys, a wholly owned subsidiary of Jubilant Pharmova Limited, has expanded its India operations with the opening of a new discovery and preclinical facility in Noida, doubling its overall chemistry capacity for discovery research and scale-up projects.

The multimillion-dollar facility combines discovery labs, early-phase scale-up capabilities, and two pilot plants, catering to growing demand for fee-for-service (FFS) contracts.

Giuliano Perfetti, CEO of Jubilant Biosys Limited, said, “We have grown rapidly over the past year, well above the wider market, by expanding our FFS offerings, which enable innovators to advance discovery projects with lower risk. With improving funding conditions, we anticipate even higher demand next year, and this new facility doubles our existing capabilities. From a client perspective, we can now provide faster discovery delivery and integrated scale-up, with projects seamlessly transferred to our GMP facilities ready for any IND filing and commercial phases.”

The Noida facility provides biotech and pharma partners a unified route from discovery to scale-up, complementing Jubilant Biosys’ existing Chemistry Research Innovation Centre (CRIC) in Greater Noida. The expansion brings the company’s scientific workforce to over 1,300 and adds multiple manufacturing lines, with several new clients already on-boarded.

Designed to handle quantities from hundreds of grams to 25 kg, the small-molecule hub features 20,000 sq ft of R&D space and 15 reactors ranging from 20L to 250L. The campus is built for future growth, with the potential to quadruple capacity as client demand increases.

Jubilant Biosys works with eight of the top 20 global pharma companies and recently reported a 42% rise in first-quarter revenue for FY26, driven by increasing FFS demand. The facility offers route scouting, process optimization, scalable synthesis, analytical services, and seamless technology transfer to pilot plants, providing end-to-end discovery and preclinical solutions.